Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer

Medical Oncology

Volumn 15, Issue 2, 1998, Pages 119-123

  Suzuki, Mitsuaki ^a   Saito, Susumu ^b   Saga, Yasushi ^a   Ohwada, Michitaka ^a   Sato, Ikuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SRL INC   (Japan)

Author keywords

6q27; Clear cell adenocarcinoma; Loss of heterozygosity; Ovarian cancer; p53

Indexed keywords

DNA; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GENETICS; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0031680722     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02989590     Document Type: Article

References (27)

1. Bertelsen K et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian cancer. Gynecol Oncol 1987; 28: 161-169.
2. Ministry of Health and Welfare of Japan. Changes in mortality rate of major malignant tumors by organ. In: Annual Report on Health and Welfare, 1997: Vital Statistics. Ministry of Health and Welfare; Tokyo; 1997.
3. Okamoto A et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991; 51: 5171-5176.
4. Fujita M et al. Alteration of the p53 tumor suppresser gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994; 85: 1247-1256.
5. Niwa K et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-1197.
6. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: A late event? Oncogene 1991; 6: 1685-1690.
7. Milner BJ et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
8. Wertheim I et al. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86: 1549-1551.
9. Kim JW et al. Aberration of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol 1995; 57: 199-204.
10. Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and lip in human ovarian carcinomas. Oncogene 1990; 5: 219-223.
11. Lee JH, Kavanagh JJ, Wildrik DM, Wharton JT, Blick M. Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. Cancer Res 1990; 50: 2724-2728.
12. Sato T et al. Allelotype of human ovarian cancer. Cancer Res 1991; 51: 5118-5122.
13. Zheng J, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/new gene amplification. Cancer Res 1991; 51: 4045-4051.
14. Saito S et al. Fine-scale deletion mapping of the distal long arm chromosome 6 in 70 human ovarian cancers. Cancer Res 1992; 52: 5815-5817.
15. Cliby W et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993; 53: 2393-2398.
16. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993; 67: 551-559.
17. Wan M et al. Three distinct regions of chromosome 6 are targets of loss of heterozygosity in human ovarian carcinomas. Int J Oncol 1994; 5: 1043-1048.
18. Orphanos V et al. Allelic imbalance of chromosome 6q in ovarian tumours. Br J Cancer 1995; 71: 666-669.
19. Cooke IE, Shelling AN, Meuth VGL, Charnock FML, Ganesan TS. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer 1996; 15: 223-233.
20. Saito S et al. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. Cancer Res 1996; 56: 5586-5589.
21. Montag AG et al. Ovarian clear cell carcinoma. Int J Gynecol Pathol 1989; 8: 85-96.
22. Jenison EL et al. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
23. Omura GA et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.
24. Sato T et al. Allelotype of breast cancer: Cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 1990; 50: 7184-7189.
25. Hsu IC et al. Mutational hotshot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428.
26. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 5520-5525.
27. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995; 72: 521-527.